File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: 4-Epidoxorubicin in recurrent cervical cancer

Title4-Epidoxorubicin in recurrent cervical cancer
Authors
Wong, LCChoy, DTKNgan, HYSSham, JSTMa, HK
Issue Date1989
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
Citation
Cancer, 1989, v. 63 n. 7, p. 1279-1282 How to Cite?
DOI: http://dx.doi.org/10.1002/1097-0142(19890401)63:7<1279::AID-CNCR2820630708>3.0.CO;2-G
AbstractThirty-eight patients with histologically proven recurrent cervical cancer were treated with epirubicin, an analogue of anthracycline. There were eight complete responders and ten partial responders. The overall response rate was 47.8%. The survival duration of the responders was significantly longer than that of the nonresponders. The optimal dose of epirubicin has yet to be determined. The dosage of 120 mg/m2 was well tolerated. The role of epirubicin as an adjuvant chemotherapeutic agent in the treatment of cervical cancer was discussed.
Persistent Identifierhttp://hdl.handle.net/10722/173154
ISSN
0008-543X
2021 Impact Factor: 6.921
2020 SCImago Journal Rankings: 3.052
ISI Accession Number ID
WOS:A1989T682600007

 

DC FieldValueLanguage
dc.contributor.authorWong, LCen_US
dc.contributor.authorChoy, DTKen_US
dc.contributor.authorNgan, HYSen_US
dc.contributor.authorSham, JSTen_US
dc.contributor.authorMa, HKen_US
dc.date.accessioned2012-10-30T06:28:13Z-
dc.date.available2012-10-30T06:28:13Z-
dc.date.issued1989en_US
dc.identifier.citationCancer, 1989, v. 63 n. 7, p. 1279-1282en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/173154-
dc.description.abstractThirty-eight patients with histologically proven recurrent cervical cancer were treated with epirubicin, an analogue of anthracycline. There were eight complete responders and ten partial responders. The overall response rate was 47.8%. The survival duration of the responders was significantly longer than that of the nonresponders. The optimal dose of epirubicin has yet to be determined. The dosage of 120 mg/m2 was well tolerated. The role of epirubicin as an adjuvant chemotherapeutic agent in the treatment of cervical cancer was discussed.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741en_US
dc.relation.ispartofCanceren_US
dc.subject.meshAdulten_US
dc.subject.meshCarcinoma, Squamous Cell - Drug Therapy - Pathologyen_US
dc.subject.meshEpirubicin - Adverse Effects - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHeart Diseases - Chemically Induceden_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Recurrence, Local - Drug Therapyen_US
dc.subject.meshUterine Cervical Neoplasms - Drug Therapy - Pathologyen_US
dc.title4-Epidoxorubicin in recurrent cervical canceren_US
dc.typeArticleen_US
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_US
dc.identifier.authorityNgan, HYS=rp00346en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/1097-0142(19890401)63:7<1279::AID-CNCR2820630708>3.0.CO;2-G-
dc.identifier.pmid2920356-
dc.identifier.scopuseid_2-s2.0-0024583609en_US
dc.identifier.volume63en_US
dc.identifier.issue7en_US
dc.identifier.spage1279en_US
dc.identifier.epage1282en_US
dc.identifier.isiWOS:A1989T682600007-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridWong, LC=7402092003en_US
dc.identifier.scopusauthoridChoy, DTK=7102939127en_US
dc.identifier.scopusauthoridNgan, HYS=34571944100en_US
dc.identifier.scopusauthoridSham, JST=7101655565en_US
dc.identifier.scopusauthoridMa, HK=7403095603en_US
dc.identifier.issnl0008-543X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats